{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma+Metastatic", "query": { "condition": "Melanoma Metastatic" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 1218, "total_pages": 122, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma+Metastatic&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-17T00:25:45.964Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01153763", "title": "A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "GSK2118436", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 92, "start_date": "2010-08-09", "completion_date": "2016-06-01", "has_results": true, "last_update_posted_date": "2017-09-27", "last_synced_at": "2026-09-17T00:25:45.964Z", "location_count": 6, "location_summary": "Los Angeles, California • San Francisco, California • Philadelphia, Pennsylvania + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01153763" }, { "nct_id": "NCT01320085", "title": "A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "BRAF or NRAS Mutant Metastatic Melanoma" ], "interventions": [ { "name": "MEK162", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 183, "start_date": "2011-03-24", "completion_date": "2023-02-06", "has_results": true, "last_update_posted_date": "2024-01-24", "last_synced_at": "2026-09-17T00:25:45.964Z", "location_count": 10, "location_summary": "Fayetteville, Arkansas • Tampa, Florida • Portland, Oregon + 3 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Tampa", "state": "Florida" }, { "city": "Portland", "state": "Oregon" }, { "city": "Portland", "state": "Oregon" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01320085" }, { "nct_id": "NCT05984615", "title": "Real-world Evaluation of the Impact of Baseline Metastases on Clinical Outcomes Among BRAF Positive Metastatic Melanoma Patients", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "BRAF Positive Metastatic Melanoma" ], "interventions": [], "intervention_types": [], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1961, "start_date": "2022-06-08", "completion_date": "2022-08-24", "has_results": false, "last_update_posted_date": "2023-08-09", "last_synced_at": "2026-09-17T00:25:45.964Z", "location_count": 1, "location_summary": "East Hanover, New Jersey", "locations": [ { "city": "East Hanover", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05984615" }, { "nct_id": "NCT05859074", "title": "A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cutaneous Squamous Cell Carcinoma", "SCC - Squamous Cell Carcinoma", "Basal Cell Carcinoma", "BCC", "BCC - Basal Cell Carcinoma", "Melanoma", "Merkel Cell Carcinoma", "Sebaceous Carcinoma", "Extramammary Paget Disease", "Kaposi Sarcoma", "Head and Neck Squamous Cell Carcinoma", "HNSCC", "Adnexal Carcinoma", "Angiosarcoma", "Cutaneous Neoplasm", "Advanced Cancer", "Metastatic Cancer", "Refractory Cancer", "Solid Tumor" ], "interventions": [ { "name": "MQ719", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2023-05-04", "completion_date": "2028-05-04", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-09-17T00:25:45.964Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05859074" }, { "nct_id": "NCT02500576", "title": "Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Melanoma", "Stage IIIB Cutaneous Melanoma AJCC v7", "Stage IIIC Cutaneous Melanoma AJCC v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7" ], "interventions": [ { "name": "Aldesleukin", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Therapeutic Tumor Infiltrating Lymphocytes", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2015-08-07", "completion_date": "2022-10-12", "has_results": true, "last_update_posted_date": "2025-01-15", "last_synced_at": "2026-09-17T00:25:45.964Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02500576" }, { "nct_id": "NCT06805825", "title": "A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastrointestinal Stromal Tumors", "Small-cell Lung Cancer", "Adenoid Cystic Carcinoma", "Uveal Melanoma", "Neuroendocrine Tumors", "Chromophobe Renal Cell Carcinoma", "Clear Cell Renal Cell Carcinoma" ], "interventions": [ { "name": "NN3201", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novelty Nobility, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2025-02-03", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2025-09-23", "last_synced_at": "2026-09-17T00:25:45.964Z", "location_count": 5, "location_summary": "Ann Arbor, Michigan • Cleveland, Ohio • Portland, Oregon + 2 more", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Portland", "state": "Oregon" }, { "city": "Houston", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06805825" }, { "nct_id": "NCT06270706", "title": "A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced or Metastatic Solid Tumor" ], "interventions": [ { "name": "PLN-101095", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pliant Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 124, "start_date": "2023-08-30", "completion_date": "2030-06", "has_results": false, "last_update_posted_date": "2026-08-03", "last_synced_at": "2026-09-17T00:25:45.964Z", "location_count": 12, "location_summary": "New Haven, Connecticut • Atlanta, Georgia • Grand Rapids, Michigan + 8 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "East Brunswick", "state": "New Jersey" }, { "city": "Lake Success", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06270706" }, { "nct_id": "NCT00701987", "title": "Safety, Tolerability, and Preliminary Efficacy Study of ALS-357 in Patients With Cutaneous Metastatic Melanoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "ALS-357", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Advanced Life Sciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2008-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2010-02-03", "last_synced_at": "2026-09-17T00:25:45.964Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00701987" }, { "nct_id": "NCT05180799", "title": "A Phase 1/2 Study of BA3071 in Patients With Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "NSCLC", "Melanoma" ], "interventions": [ { "name": "BA3071", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pemetrexed (Alimta)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "BioAtla, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 320, "start_date": "2022-08-03", "completion_date": "2026-06-30", "has_results": false, "last_update_posted_date": "2025-06-15", "last_synced_at": "2026-09-17T00:25:45.964Z", "location_count": 9, "location_summary": "Los Angeles, California • Atlanta, Georgia • Dyer, Indiana + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Dyer", "state": "Indiana" }, { "city": "Morristown", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05180799" }, { "nct_id": "NCT00026221", "title": "Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Melanoma", "Stage IV Skin Melanoma" ], "interventions": [ { "name": "Recombinant Interferon Alfa", "type": "BIOLOGICAL" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2001-11", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2016-03-17", "last_synced_at": "2026-09-17T00:25:45.964Z", "location_count": 2, "location_summary": "Cincinnati, Ohio • Columbus, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00026221" } ] }